Dirk Brehmer

Achievements: 2025 Global License: Allianthera (China) 2024 M&A: Kynos Therapeutics (UK) 2023 License: Neopharmed (IT) 2022 Alliance: Takeda (Global) 2021 EU License Renexxion (USA/IR) 2020 EU License Prometheus Biosciences Responsibilities: - Strategy (Science & Development Pipeline & Commercials) - Gastroenterology, Hepatology and Oncology - Global External Innovation: pre-clinical, Ph1-3, and commercialized products - Global Business Development, In & Out-licensing, M&A - Alliance Management - Deep Scientific Evaluations - Market Research - Strategic Pipelinemanagement - SLT Member

Have built the global infrastructure for external innovation including the implementation of innovation champions as part of the established stronghold concept. Built the road map for global and active scouting, scientific and commercial due diligence, BD and licensing as well as alliance management.

External innovation and partnering role as an expansion of my responsibility as Scientific Director and Group Leader for Pre-Clinical Research and Early Clinical Development. Opportunities Scouting, Due Diligence, and Alliance Management for Oncology

Oncology therapeutic area; globally acting group leader for the discovery and development of small and large molecule inhibitors (pre-clinic/Ph1) at Janssen Pharmaceutica, a division of Johnson & Johnson in Beerse, Belgium Built an innovative preclinical program pipeline engine applying diverse treatment modalities as well as different biological concepts to fuel the early clinical development pipeline against solid tumors. Several programs reached NME status and are tested in the clinic e.g. JNJ-64619178 best in class PRMT5i (Onametostat); JNJ-78306358 is a first-in-class HLA-G and CD3 bispecific antibody - Had the luxury of building and working with a highly dedicated team - Drug Discovery, Pharmacology, Translational Research & early Clinical Development - Small molecules (reversible and irreversible, degrader), antibodies (bispecifics, redirection, ADC, ADCC) - Built the foundation of the epigenetic platform at J&J by running several high-priority programs with different targets and modalities - Initiated and supported the J&J degrader concept for solid tumor targets - Johnson & Johnson Leadership Award eg for JNJ-64619178, a best-in-class PRMT5 inhibitor - Member of the Senior Leadership Team

Oncology therapeutic area, team leader for small and large molecule inhibitors at Janssen Pharmaceutica, a division of Johnson & Johnson in Beerse, Belgium. - From target identification to New-Molecular-Entity (NME): e.g.Erdafitinib (FGFRi), JNJ-38877605 (C-METi), and JNJ-26483327 (EGFRi). - Scientific grants application winner > 5M Euro from the Flemish Government for Science and Innovation. Built a European Academic Network to explore new small molecule concepts for targeting the conformational plasticity. - Scientific Liaison: MIT, Dundee and Edinburgh; Forma Therapeutics and Astex Therapeutics exploring several novel anti-cancer biology, targets and treatment modalities.

Co-founding/ Start-Up member of Kinaxo Biotechnology, an innovative and internationally leading company in the field of chemical proteomics & phospho-proteomics for compound profiling and identification of bio- and diagnostic maker(s). Group Leader for chemical biology/ proteomics/ kinase drug discovery and client/ project management.

Lab/ Project lead for novel type II kinase inhibitors (hit-ID to lead optimization). Initiated a type-II kinase fragment library based on chemical proteomics that led to the scientific foundation of Proteros Fragments GmbH.

Kinase drug discovery and chemical proteomics

Exploration of chaperone-assisted protein folding as a basic for general drug discovery targeting the conformational plasticity in a disease content - Protein purification and folding - Biophysical analyses of ligand-protein and protein-protein interactions - Enzyme kinetics - Molecular biology

Molecular Chaperones, Prof. Bernd Bukau Nominated for best PhD thesis in 2000/2001